Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer.

Slides:



Advertisements
Similar presentations
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.
Advertisements

TACE for HCC in a regional centre: 5 year audit and assessment of baseline predictors of outcome Iain DS Morrison, #R Kasthuri, EH Forrest, S Barclay,
Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic.
Paroxetine, Cognitive Therapy or Their Combination in the Treatment of Social Anxiety Disorder with and without Avoidant Personality Disorder: A Randomized.
Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias Acta.
Case Rep Oncol 2017;10:462– DOI: /
Cognitive Therapy versus Fluvoxamine as a Second-Step Treatment in Obsessive-Compulsive Disorder Nonresponsive to First-Step Behavior Therapy Psychother.
The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent.
Analysis of endometrial carcinoma in young women at a high-volume cancer center  Alper Biler, Ulas Solmaz, Selcuk Erkilinc, Mehmet Gokcu, Mustafa Bagci,
Can the American Thyroid Association Risk of Recurrence Predict Radioiodine Refractory Disease in Differentiated Thyroid Cancer Eur Thyroid J 2016;5:
The Effect of Retraining on Treatment Success, Quality of Life, and Metabolic Parameters in Patients with Type 1 Diabetes Using an Insulin Pump Med Princ.
Quantitative Renal Echogenicity as a Tool for Diagnosis of Advanced Chronic Kidney Disease in Patients with Glomerulopathies and no Liver Disease Kidney.
The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy Kidney Blood Press Res 2016;41: DOI: /
BCLC Outperforms HKLC Staging of Hepatocellular Carcinoma in Multiethnic Asians – Real-World Perspective ESPS Manuscript NO:
Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program Cardiorenal Med 2011;1:45–52 - DOI: /
Management of Breast Cancer Patients with Chemotherapy-Induced Neutropenia or Febrile Neutropenia Breast Care 2014;9: DOI: / Fig.
Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.
Treatment of Multiple Actinic Keratosis and Field of Cancerization with Topical Piroxicam 0.8% and Sunscreen 50+ in Organ Transplant Recipients: A Series.
Oncol Res Treat 2016;39: DOI: /
The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis Urol Int 2017;99:
Radioembolization for hepatocellular carcinoma
Baicalein, a Natural Anti-Cancer Compound, Alters MicroRNA Expression Profiles in Bel-7402 Human Hepatocellular Carcinoma Cells Cell Physiol Biochem 2017;41:1519–1531.
The Impact of Case Finding on the Recruitment Yield for COPD Research in Primary Care: An Observational Study Respiration 2016;92: DOI: /
Clinical outcome after SVR: Veterans Affairs
Evaluating Quality in Clinical Cancer Research: The M. D
Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /
Electrochemotherapy in the Treatment of Massive, Multisite Breast Cancer Metastasis to the Skin and Subcutaneous Tissue: A Case Report Breast Care 2016;11:
Is Anti-Hepatitis C Virus Antibody Level an Appropriate Marker to Preclude the Need for Supplemental Testing? Intervirology 2015;58: DOI: /
Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy  Jae.
Elevated FOXC2 Expression Promotes Invasion of HCC Cell Lines and is Associated with Poor Prognosis in Hepatocellular Carcinoma Cell Physiol Biochem 2017;44:99–109.
Cell Physiol Biochem 2016;40: DOI: /
Supplementary Table 1. Dissociation cases of EI and Fibrosis Case 1 2
Volume 146, Issue 7, Pages e3 (June 2014)
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
ZNF750 Expression Is a Potential Prognostic Biomarker in Esophageal Squamous Cell Carcinoma Oncology - DOI: / Fig. 1. The immunohistochemical.
Volume 68, Issue 5, Pages (May 2018)
MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma Liver Cancer 2017;6: DOI: /
A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial.
Successful Treatment with S-1 and Oxaliplatin Combination Therapy in an Elderly Patient with Metastatic Colorectal Cancer Initially Presenting with Membranous.
Chronic Hepatitis B Infection is Associated with Decreased Risk of Preeclampsia: A Meta-Analysis of Observational Studies Cell Physiol Biochem 2016;38:
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic.
Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients Breast Care 2016;11: DOI: / Fig. 1. Strategies.
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
Early Systolic Blood Pressure Changes in Incident Hemodialysis Patients Are Associated with Mortality in the First Year Kidney Blood Press Res 2012;35:663–670.
Marcus-Alexander Wörns, Peter Robert Galle  Journal of Hepatology 
Cell Physiol Biochem 2016;39: DOI: /
Hepatitis B and C virus-related carcinogenesis
Volume 152, Issue 8, Pages (June 2017)
Clinical outcome after SVR: ANRS CO22 HEPATHER
Volume 145, Issue 1, Pages (July 2013)
Volume 146, Issue 7, Pages e3 (June 2014)
Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,
A Pathological Scoring System to Predict Renal Outcome in Diabetic Nephropathy Am J Nephrol 2015;41: DOI: / Fig. 1. Renal survival.
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia  Paul M. Armistead, Marcos.
Radioembolization for hepatocellular carcinoma
Volume 57, Issue 4, Pages (October 2012)
Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study  J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.
Enrollment and Outcomes
Hepatitis B and C virus-related carcinogenesis
Payan Schober et al. Am J Nephrol 2017;45:   (DOI: / )
Volume 70, Issue 4, Pages (April 2019)
New trials and results in systemic treatment of HCC
Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular.
Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy  Jae.
Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.
Multidisciplinary team approach to hepatocellular carcinoma management in a liver transplant center from Romania Cerban R.1, Iacob S.1, Croitoru A.1, Popescu.
Reversion of disease manifestations after HCV eradication
Friedrich Foerster, Peter Robert Galle  JHEP Reports 
Presentation transcript:

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer 2017;6:313-324 - DOI:10.1159/000480441 Fig. 1. Study flow chart. © 2017 S. Karger AG, Basel

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer 2017;6:313-324 - DOI:10.1159/000480441 Fig. 2. Kaplan-Meier curves describing the overall survival of patients with hepatocellular carcinoma treated with sorafenib according to prior treatment status (pre-treated or treatment naïve) (a), BCLC stage (b), and aetiology of the underlying cirrhosis (c). BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus. © 2017 S. Karger AG, Basel

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer 2017;6:313-324 - DOI:10.1159/000480441 Fig. 3. Kaplan-Meier curves describing the differences in overall survival of patients classified according to prior treatment status following stratification by the type of therapy received after permanent sorafenib cessation: best supportive care (BSC) (a) or further active anticancer therapies (b). © 2017 S. Karger AG, Basel

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer 2017;6:313-324 - DOI:10.1159/000480441 Table 1. Clinicopathologic features at study baseline © 2017 S. Karger AG, Basel

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer 2017;6:313-324 - DOI:10.1159/000480441 Table 2. Univariate and multivariate analyses of survival © 2017 S. Karger AG, Basel

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer 2017;6:313-324 - DOI:10.1159/000480441 Table 3. Comparison of radiologic responses and the post-sorafenib treatment status between the pre-treated and treatment-naïve patients © 2017 S. Karger AG, Basel

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.